(CLVS) Stock Rating Reaffirmed by Morgan Stanley

Alain Brian
Août 13, 2017

They now have a $93.00 price objective on the biopharmaceutical company's stock. Equity analyst Leerink Swann began coverage of the stock setting a rating of "Outperform". J P Morgan Chase & Co set a $72.00 target price on Clovis Oncology and gave the stock a "buy" rating in a research report on Thursday, June 1st. SunTrust Banks, Inc. reissued a "buy" rating on shares of Clovis Oncology in a research report on Thursday, June 22nd. The company has market cap of $3.47 billion. Morgan Stanley reissued an "overweight" rating and issued a $79.00 target price on shares of Clovis Oncology in a report on Tuesday, May 2nd.

On July 7, 2017 Gabelli & Co. starting coverage on CLVS giving it an initial rating of "Buy". Stifel Nicolaus maintained it with "Buy" rating and $86 target in Monday, January 23 report. On June 23, 2017 Oppenheimer added the stock to its research portfolio with a rating of "Market Perform".

On June 19 the company was upgraded from "Sell" to "Outperform" and a price target of $85.00 was set by Chardan Capital. WallachBeth Capital maintained Clovis Oncology Inc (NASDAQ:CLVS) on Wednesday, December 21 with "Hold" rating. Jasper Ridge Partners L.P. now owns 9,184 shares of the biopharmaceutical company's stock valued at $585,000 after buying an additional 4,592 shares in the last quarter. Clovis Oncology, Inc. has a 52 week low of $16.58 and a 52 week high of $99.45. The company's 50-day moving average price is $87.91 and its 200-day moving average price is $66.98. The firm earned "Sell" rating on Friday, February 3 by Chardan Capital Markets. Bancorporation Of America De reported 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.27) by $0.02. The business had revenue of $14.62 million during the quarter, compared to analyst estimates of $13.07 million. Cornerstone Mngmt Company has 0% invested in Clovis Oncology Inc (NASDAQ:CLVS) for 1,200 shares. During the same period past year, the business earned ($2.07) earnings per share. Analysts anticipate that Clovis Oncology, Inc. will post ($7.51) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & global copyright & trademark legislation. More interesting news about Clovis Oncology Inc (NASDAQ:CLVS) were released by: Nasdaq.com and their article: "Clovis Oncology Enters Oversold Territory (CLVS)" published on August 09, 2017 as well as Thestreet.com's news article titled: "One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?" with publication date: August 03, 2017. The shares were sold at an average price of $47.39, for a total value of $142,170.00. Following the completion of the transaction, the insider now owns 200,583 shares of the company's stock, valued at approximately $12,400,041.06. The sale was disclosed in a filing with the SEC, which is accessible through this link.

In other news, Director James C. Blair sold 18,450 shares of the business's stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $78.61, for a total transaction of $1,450,354.50. Following the transaction, the director now directly owns 2,185 shares of the company's stock, valued at approximately $171,762.85. The disclosure for this sale can be found here.

As of quarter end Alliancebernstein L.P. had bought a total of 204,599 shares growing its holdings by 27.1%. 1,287,020 shares of the company's stock were exchanged. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Clovis Oncology by 71.4% in the first quarter. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company's stock worth $84,788,000 after buying an additional 1,318,669 shares during the period. Manufacturers Life Insurance The invested 0% of its portfolio in Clovis Oncology Inc (NASDAQ:CLVS). PNC Financial Services Group Inc. raised its position in Clovis Oncology by 3.7% in the first quarter. Franklin Resources Inc augmented its ownership by buying 687,300 shares an increase of 70.3% from 03/31/2017 to 06/30/2017. Wellington Management Group LLP increased its position in Clovis Oncology by 10,143.6% in the first quarter.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets. The Company's product candidates include Rociletinib, Rubraca and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the fix of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

D'autres rapports CampDesrEcrues

Discuter de cet article